RBCC: Alzheimer’s Epidemic Draws $100 Million in Research

  RBCC: Alzheimer’s Epidemic Draws $100 Million in Research

Business Wire

NOKOMIS, Fla. -- October 24, 2012

As Rainbow Coral Corp.’s (OTCBB:RBCC) biotech subsidiary, Rainbow BioSciences,
nears a deal with Amarantus BioSciences (OTCBB: AMBS), the Alzheimer’s
epidemic is already drawing $100 million worth of disease research from big
drug companies.

A $100 million drug trial will begin next year in the isolated villages of
Antioquia, Columbia, where a genetic mutation in the community’s blood line
has led to a higher concentration of Alzheimer’s sufferers than anywhere else
in the world. About 5,000 residents of the area now form the biggest and best
pool of potential Alzheimer’s patients anywhere—a solid trial group for drug
companies working on a cure.

“This massive research expenditure in Columbia just goes to show how desperate
the world is for a cure to this disease,” said RBCC CEO Patrick Brown. “There
is a huge a market developing around the globe for effective new Alzheimer’s
treatments, and we’re working very hard to capitalize on that demand.”

Last week, RBCC prepared a term sheet for presentation to Amarantus, a
clinical-stage company developing therapeutics designed to reverse cell death
caused by Parkinson’s disease. Alzheimer’s, which is much more common, also
results from neuronal proteins. Therefore, it is believed that the same
treatment could prove beneficial to these patients thereby vastly increasing
the market for the therapy.

For more information on Rainbow BioSciences’ neurological treatment
initiatives, please visitwww.rainbowbiosciences.com/investors.html.

RainbowBioSciences is dedicated to developing new medical and research
technology innovations to compete alongside companies such as Amgen Inc.
(NASDAQ:AMGN),Cell Therapeutics, Inc. (NASDAQ:CTIC), Abbott Laboratories
(NYSE:ABT) andAffymax, Inc.(NASDAQ:AFFY).

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp.
(OTCBB:RBCC). The company continually seeks out new partnerships with
biotechnology developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business initiatives,
please visit our website at [www.RainbowBioSciences.com]. For investment
information and performance data on the company, please visit
www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the company assumes no responsibility to update the information included
herein for events occurring after the date hereof.

Contact:

Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
info@rainbowcoral.com
 
Press spacebar to pause and continue. Press esc to stop.